Please ensure Javascript is enabled for purposes of website accessibility
ホーム > 製品 > 抗体 > バイオシミラー

Research Grade Anti-Human CD274/PD-L1/B7-H1 (FAZ053) (HV974356)

Research Grade Anti-Human CD274/PD-L1/B7-H1 (FAZ053)
Research Grade Anti-Human CD274/PD-L1/B7-H1 (FAZ053)
価格(USD): $
スペック:
  • 100ug
  • 1mg
数量:
お問い合わせ
  • 概要

  • イメージ

  • 参考文献

  • データシート

概要
カタログ番号HV974356
説明
Anti-Human CD274/PD-L1/B7-H1 (FAZ053) (HV974356) is a research-grade recombinant antibody targeting CD1. Produced in mammalian cells with native-like glycosylation.
Highlights
  • Research Grade — For PK/PD studies, assay development, and ADA research.
  • Native Glycosylation — Mammalian expression ensures native-like patterns.
種反応性Human
アプリケーションELISA, Bioactivity: FACS, Functional assay, Research in vivo
宿主種Human
アイソタイプIgG
クローンIDFAZ053
発現システム Mammalian Cells
クローン性 Monoclonal
ターゲット B7-H1, Programmed cell death 1 ligand 1, PDCD1 ligand 1, PDCD1L1, B7 homolog 1, PDCD1LG1, PDL1, hPD-L1, Programmed death ligand 1, B7H1, PD-L1, CD274
エンドトキシンレベル Please contact the lab for this information.
純度 >95% purity as determined by SDS-PAGE.
精製 Protein A/G purified from cell culture supernatant.
アクセッション番号 Q9NZQ7
形態 Liquid
保存バッファー 0.01M PBS, pH 7.4.

データシートのハードコピーまたはロット固有のCOAに記載された具体的なバッファー情報を参照してください。

安定性と保存 Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
別名FAZ053
背景

Programmed cell death 1 ligand 1 (CD274/PD-L1) is a ~33 kDa protein. Plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response. Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10). Can also act as a transcription coactivator: in response to hypoxia, translocates into the nucleus via its interaction with phosphorylated STAT3 and promotes transcription of GSDMC, leading to pyroptosis. CD274 is the therapeutic target of atezolizumab (Tecentriq) and durvalumab (Imfinzi).

1. Freeman, GJ. et al. (2000) The Journal of experimental medicine 192, 1027-34. PMID: 11015443
2. Mezzadra, R. et al. (2017) Nature 549, 106-110. PMID: 28813410
3. Burr, ML. et al. (2017) Nature 549, 101-105. PMID: 28813417
4. Huang, X. et al. (2019) Cancer immunology research 7, 1580-1590. PMID: 31399419
5. Kennedy, A. et al. (2023) The EMBO journal 42, e111556. PMID: 36727298
6. Dong, H. et al. (1999) Nature medicine 5, 1365-9. PMID: 10581077
7. Hou, J. et al. (2020) Nature cell biology 22, 1264-1275. PMID: 32929201
注意事項 For research use only. Not suitable for clinical or therapeutic use.
イメージ
  • Research Grade Anti-Human CD274/PD-L1/B7-H1 (FAZ053)

    SDS-PAGE

    SDS-PAGE for Research Grade Anti-Human CD274/PD-L1/B7-H1 (FAZ053)

参考文献
Formula
Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)
Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.
Mass
=
Concentration
×
Volume
Molecular Weight *
g/mol
Formula
C₁ × V₁ = C₂ × V₂
Enter any 3 of the 4 values to solve for the unknown.
Stock Solution
C₁ (Stock Conc.)
×
V₁ (Stock Vol.)
=
Working Solution
C₂ (Working Conc.)
×
V₂ (Working Vol.)
レコメンデーション

お問い合わせ カスタムクォート、大量リクエストおよびその他の問題については

メール: support@abinScience.com

ディストリビューターリスト